Resources
23 Results (showing 11 - 20)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/29/2020 (updated 3/28/2024)
This Guide on Prevention of Drug Use and Treatment of Drug Use Disorder in Rural Settings was prepared by the United Nations Office on Drugs and Crime Drug Prevention and Health Branch, in the context of the global project Treatnet II: OFID-UNODC Programme to prevent HIV/AIDS through Treatnet Phase II, with the aim of providing an awareness-raising tool and guidance for policymakers, public health officials, local authorities and other stakeholders in dealing with substance use issues in rural settings in their respective countries.
Posted 5/12/2020 (updated 3/28/2024)
The Clinical Opiate Withdrawal Scale is an 11-item scale designed to be administered by a clinician.
Posted 5/12/2020 (updated 3/28/2024)
The CIWA-Ar assessment for monitoring withdrawal symptoms requires approximately 5 minutes to administer. The maximum score is 67. Patients scoring less than 10 do not usually need additional medication for withdrawal.
Posted 8/24/2020 (updated 3/28/2024)
Lessons Learned From Listening Sessions With Five Tribes in Minnesota.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Rapid Fire Session was held in the Independence Ballroom Salons D & E on Friday, March 6, 2020, at 9:00 AM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Capitol Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 11/9/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) published Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants in 2018. The National Center on Substance Abuse and Child Welfare (NCSACW) developed companion materials that offer information and strategies to support pregnant and parenting people with substance use disorders (SUDs) in the child welfare system.
Posted 2/14/2023 (updated 3/27/2024)
This systematic review of peer-reviewed literature that held controlled trails which examined a pharmacological treatment for amphetamine/methamphetamine dependence or use disorder. The article found that most studies were underpowered and had low completion rates, with others showing that no pharmacotherapy produced results for the treatment of amphetamine/methamphetamine dependence.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 12/13/2022 (updated 3/27/2024)